Skip to main content
Premium Trial:

Request an Annual Quote

Sankyo Subscribes to LifeSpan Database

NEW YORK, July 24-The Japanese pharmaceutical company Sankyo has subscribed to the nuclear receptor module of LifeSpan BioScience's drug target database, LifeSpan said yesterday.

 

Sankyo will use the database to help in drug target validation for diseases like diabetes, cancer and obesity. It includes immunohistochemical data and public sequence and localization data on more than 2,000 genes.

 

LifeSpan's database includes information on gene families of interest for drug discovery, and has eight modules. Sankyo also subscribes to the company's G-protein coupled receptor database module.

 

Nuclear receptors regulate gene activity related to homeostasis, development and differentiation, and have been implicated in cancer, metabolic diseases, rheumatoid arthritis and other disorders.

 

LifeSpan BioScience is based in Seattle.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.